Living with rheumatoid arthritis means watching for signs that your disease is flaring up. Doctors often rely on blood tests like ESR and CRP, but these can be slow to change. A new study offers a sharper way to see what is happening inside the joints right now. Researchers tested a combined model that uses musculoskeletal ultrasound and a machine learning algorithm to assess disease activity. They compared this to ultrasound alone and a different imaging method called radiomics. The results showed the combined model was the most accurate at predicting when the disease was active. It found specific signs like high blood flow in the joint lining that signal a flare. This approach helps clinicians monitor patients more dynamically and choose the right medical strategies for their specific needs. While the study involved patients from two hospitals in China, the potential to improve routine care is clear. By providing a reliable imaging basis, this tool supports better decisions without adding unnecessary risk or cost.
Combined MSK US and machine learning model improves rheumatoid arthritis disease activity assessmentCombined ultrasound and AI model best predicts rheumatoid arthritis activity
AI-generated summary of the cited source, checked by automated accuracy review. How we work
This was a prospective, two-center diagnostic study involving 203 patients with clinically confirmed rheumatoid arthritis. The intervention was a combined model integrating musculoskeletal ultrasound (MSK US) with a machine learning algorithm. Comparators were an MSK US model alone and a radiomics model alone. The primary outcome was assessing rheumatoid arthritis disease activity.
In the training cohort, the area under the curve (AUC) was 0.935 (95% CI: 0.893-0.978) for the MSK US model, 0.976 (95% CI: 0.955-0.997) for the radiomics model, and 0.998 (95% CI: 0.998-1.000) for the combined model. In the independent external test cohort, the AUC was 0.904 (95% CI: 0.825-0.983) for the MSK US model, 0.823 (95% CI: 0.714-0.933) for the radiomics model, and 0.929 (95% CI: 0.866-0.992) for the combined model.
Decision curve analysis indicated a significant net benefit for the combined model across threshold probability ranges of 0.02–0.80 in the training cohort and 0.12–0.78 in the test cohort. Independent predictors of clinically active RA included erythrocyte sedimentation rate (ESR) >54 mm/h, C-reactive protein (CRP) >32.83 mg/L, and SMI synovial blood flow grade III.
No adverse events, serious adverse events, discontinuations, or tolerability data were reported. Key limitations include the observational design, lack of reported follow-up, and absence of safety data. The practice relevance suggests the model could enable clinicians to dynamically monitor RA disease activity and evaluate treatment response, providing a basis for treatment strategy selection.